Wise Pharmacy Recalls Papaverine, Phentolamine, and Alprostadil Injectable Vials
Wise Pharmacy is recalling 84 vials of compounded Papaverine/Phentolamine/Alprostadil injectable due to a lack of processing controls.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 2/5 (Moderate).
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class II, and the source text does not report any illnesses or injuries, fitting the criteria for a moderate severity score.
Plain-English summary
Wise Pharmacy, located in Littleton, Colorado, is recalling 84 vials of Papaverine/Phentolamine/Alprostadil 30 mg/0.2 mg/10 mcg/mL Injectable. The product is a prescription-only compounded medication distributed in Colorado, Texas, and Wyoming.
The recall was initiated due to a lack of processing controls. Specific lot numbers and expiration dates are not provided in the source text.
Consumers who have this product should contact their healthcare provider or Wise Pharmacy for further instructions on how to proceed.
The recalled product
- Product
- Papaverine/Phentolamine/Alprostadil 30 mg/0.2 mg/10 mcg/mL Injectable, 2.5 mL Vial, Rx only, Compounded by Wise Pharmacy, Littleton, CO 80123.
- Manufacturer
- Wise Pharmacy
- Category
- Drug — Compounded Injectable
- Affected units
- 84
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (5)
- Lot #: 6054N
- 4796N
- Exp 7/16/2019
- 7049N
- Exp 11/24/2019
Distribution
Part of a larger recall action
This product is one of 11 recalled by Wise Pharmacy under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 11 products in this recall →Related recalls
Same manufacturer · Wise Pharmacy
See all →- ModerateWise Pharmacy Recalls Dexamethasone Sodium Phosphate Injection Due to Processing Controls
FDA (Drugs) · 2019-08-07
- SevereWise Pharmacy Recalls Compounded Papaverine Injectable Due to Processing Controls
FDA (Drugs) · 2019-08-07
- SevereWise Pharmacy Recalls Acetylcysteine Otic Drops Due to Processing Controls
FDA (Drugs) · 2019-08-07
- ModerateWise Pharmacy Recalls Gentamicin Irrigation Solution Due to Processing Controls
FDA (Drugs) · 2019-08-07
- ModerateWise Pharmacy Recalls Papaverine/Phentolamine Injectable Due to Processing Controls
FDA (Drugs) · 2019-08-07
Same hazard · lack of processing controls
See all →- ModerateMasterPharm Recalls Vardenafil Troches Due to Lack of Processing Controls
FDA (Drugs) · 2020-08-05
- ModerateMasterPharm Recalls Progesterone Capsules Due to Processing Control Deficiencies
FDA (Drugs) · 2020-08-05
- ModerateMasterPharm Recalls Progesterone Troches Due to Lack of Processing Controls
FDA (Drugs) · 2020-08-05
- ModerateMasterPharm Recalls Yohimbine HCL Capsules Due to Processing Control Deficiencies
FDA (Drugs) · 2020-08-05
- ModerateMasterPharm Recalls Calcium Citrate Powder Due to Processing Control Deficiencies
FDA (Drugs) · 2020-08-05
Similar recalls
- SevereFDA Recalls Papaverine, Phentolamine, and Alprostadil Injectable Due to Sterility Concerns
FDA (Drugs) · 2014-11-12
- High
- Severe
- SevereFDA Recalls Papaverine-Phentolamine Injectable Due to Insanitary Compounding Conditions
FDA (Drugs) · 2019-04-17
- HighFDA Recalls Compounded Papaverine-Phentolamine-PGE1 Injectable Due to Insanitary Conditions
FDA (Drugs) · 2019-04-17
- SevereInnovative Compounding Pharmacy Recalls Alprostadil Injection Due to Sterility Concerns
FDA (Drugs) · 2020-04-15